DISHMAN SIGNED A CO-OPERATION & JOINT API DEVELOPMENT AGREEMENT WITH POLPHARMA - POLAND
Dishman Pharma - India and Polpharma - Poland have signed a cooperation and joint API development agreement. Polpharma is in particularly a strong player in its home market and a leader in the Central and Eastern European markets and CIS countries with a turnover of ca 400 million US dollars. Polpharma is also a CEE leader in the API sales with almost 90% of which in regulated markets including USA. Dishman group, a dedicated CRM player has ca. 200 million US dollars turnover. Both companies feel that this partnership will benefit mutually and pave the way for a stronger growth in coming years.
Theo Iliopoulos, Polpharma VP Operations and General Manager Fine Chemical said:
“As the Development and Manufacturing model changes and the Regulatory requirements become ever stricter it is crucial for Development and Manufacturing to adjust and build partnerships and networks with other groups. It will allow us to come up with solutions to meet the market expectations and sustain the increased competition between major pharmas and generic pharmas and solve different problems”. “This is the unprecedented power of doing things together" he argued, “it is the future of the pharmaceutical industry”. “Looking for such partnerships with academic centers, service providers with innovative technologies and development laboratories of proven efficiency is the way forward for an industry facing fierce competition”.
J R Vyas, Managing Director of Dishman said:
"Dishman has now strategies to cooperate with leading API players and pharma companies such as Polpharma with their strength in R&D and API plants in India as CRAM player. Such partnerships will ensure long term API manufacturing contracts to Dishman and also provide API development and DMF preparation capabilities to partners to cut short their time to market."
